ArticleJournal of cheminformatics2026
Integrating artificial intelligence and manual curation to enhance bioassay annotations in ChEMBL.
Article in Journal of cheminformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- AI semantics for biomedical data integration.bioRxiv : the preprint server for biology · 2026Article
- Correction: Integrating artificial intelligence and manual curation to enhance bioassay annotations in ChEMBL.Journal of cheminformatics · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
Abstract
As the volume and diversity of bioactivity data in ChEMBL continues to grow, ensuring that assay metadata is standardized, interoperable, and machine-readable is critical for effective use in cheminformatics and ML applications. In this work, we present recent efforts to enhance the quality and granularity of bioassay annotations in ChEMBL through a combination of manual and semi-manual curation and AI-driven approaches. We introduce a "perfect assay description" template to guide consistent annotation and demonstrate how natural language processing techniques and multi-class classification can be used to automatically extract key assay parameters and assign broad assay categories for legacy data. We report on the development, validation, and application of a spaCy-based NER model that identifies experimental methods with high precision and recall, as well as a complementary classification model that refines ASSAY_TYPE categorization beyond the existing schema. In addition, we describe improvements to metadata extraction for ADME endpoints, organism and protein variant annotations, and ontology linking using tools such as text2term. Together, these enhancements significantly advance the FAIRness of ChEMBL's bioassay data, enabling more robust downstream analyses and more precise compound-target activity modeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.